Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study

INTRODUCTION: Mechanical heart valves (MHV) are extremely durable, but they require permanent use of anticoagulation to prevent thromboembolic events. The only approved therapeutic options are vitamin K antagonists (VKAs), such as warfarin. As a drug class, clinical management is difficult, therefor...

Descripción completa

Detalles Bibliográficos
Autores principales: Durães, André R., de Souza Lima Bitar, Yasmin, Filho, José Admirço L., Schonhofen, Igor S., Camara, Edmundo J. N., Roever, Leonardo, Cardoso, Hugo E. D. P., Akrami, Kevan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277324/
https://www.ncbi.nlm.nih.gov/pubmed/30293126
http://dx.doi.org/10.1007/s40268-018-0249-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277324/
https://www.ncbi.nlm.nih.gov/pubmed/30293126
http://dx.doi.org/10.1007/s40268-018-0249-5

Ejemplares similares